CSL, a Melbourne, Australia-based bio/pharmaceutical company, has opened a new $900-million plasma fractionation facility in Broadmeadows, Victoria, Australia. The new facility is part of a $2 billion-plus capital investment program CSL currently has underway in Australia. 

Plasma fractionation is the process of separating the components of human blood plasma. The new facility creates protein-rich plasma pastes that are then processed into finished biotherapy products in other facilities at the site. 

The new facility allows CSL’s manufacturing site to process up to 9.2 million plasma-equivalent liters per annum, which is a nine-fold increase of current capacity for the site. The new facility has received approval by the Australian Therapeutic Goods Administration and is expected to be fully operational from early 2023. 

The facility is part of CSL’s $2-billion-dollar-plus investment program focused on Australia, which also includes an influenza vaccine0manufacturing facility for CSL Seqirus in Tullamarine, and CSL’s new global headquarters and R&D facilities in Melbourne’s biomedical precinct. 

Source: CSL